Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)-Reference-Cited by-同舟云学术

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)

Published:2018-02-09 Issue:5 Volume:21 Page:819-830
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Jung Minkyu,Ryu Min-Hee,Oh Do Youn,Kang Myounghee,Zang Dae Young,Hwang In Gyu,Lee Keun-Wook,Kim Ki Hyang,Shim Byoung Yong,Song Eun Kee,Sym Sun Jin,Han Hye Sook,Park Young Lee,Kim Jin Soo,Lee Hyun Woo,Lee Moon Hee,Koo Dong-Hoe,Song Hong Suk,Lee Namsu,Yang Sung Hyun,Choi Dae Ro,Hong Young Seon,Lee Kyoung Eun,Maeng Chi Hoon,Baek Jin Ho,Kim Samyong,Kim Yeul Hong,Rha Sun Young,Cho Jae Yong,Kang Yoon-Koo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s10120-018-0806-1/fulltext.html

Reference21 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65:87–108.

2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

3. Bang Y, Kim Y, Yang H, Chung HC, Park Y, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

4. Leung WK, Wu M, Kakugawa Y, Kim J, Yeoh K, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.

5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review;Advances in Therapy;2024-04-15

2. Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population;Life;2023-12-05

3. Gastric cancer presenting with ramucirumab-related gastrocolic fistula successfully managed by colonic stenting: a case report;Clinical Endoscopy;2023-11-30

4. Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report;Frontiers in Oncology;2023-11-09

5. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis;Advanced Science;2023-10-20